Quince Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Quince Therapeutics (QNCX).

Price Target Range — 8 Quarters

Analyst Consensus — 10 Analysts

2S.Buy

7Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$1053Upside to Avg. PT+3504.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	Rodman & Renshaw	Seema Sheoran	Initiate	Buy	$70
Sep 22, 2026	Citizens	Jonathan Wolleben	Upgrade	Market Perform→Market Outperform	$77
Aug 18, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Maintained	Overweight	$70
Jul 29, 2026	Oppenheimer	Mazahir Alimohamed	Initiate	Outperform	$82
Jun 24, 2026	Leerink Partners	Joseph Schwartz	Initiate	Outperform	$4
Jun 23, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Initiate	Overweight	$4
Jan 30, 2026	Citizens	Jonathan Wolleben	Downgrade	Market Outperform→Market Perform	—
Jan 30, 2026	D. Boral Capital	Jason Kolbert	Downgrade	Buy→Hold	—
Jan 29, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$5
Dec 15, 2025	D. Boral Capital	Jason Kolbert	PT Raise	Buy	$4→$5
Nov 13, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$4
Sep 26, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$4
Aug 15, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$4
Aug 12, 2025	JMP Securities	Jonathan Wolleben	PT Cut	Market Outperform	$9→$8
Aug 5, 2025	JMP Securities	Jonathan Wolleben	Initiate	Market Outperform	$9
Jul 17, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$4
Jun 13, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$4
Jun 4, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$4
Mar 25, 2025	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$12→$4
Mar 24, 2025	Oppenheimer	Leland Gershell	Initiate	Outperform	$10

More with Benzinga EdgeGet Access

Analyst Ratings News

This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70; EFSC Buy, $70.

Avi Kapoor

PRO
Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Buy rating and announces Price Target of $70.

Benzinga Newsdesk

PRO
Citizens Upgrades Quince Therapeutics to Market Outperform, Announces $77 Price Target

Citizens analyst Jonathan Wolleben upgrades Quince Therapeutics (NASDAQ:QNCX) from Market Perform to Market Outperform and announces $77 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) with a Overweight and maintains $70 price target.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $82.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4

Leerink Partners analyst Joseph Schwartz initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $4.

Benzinga Newsdesk

Quince Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Quince Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70

PRO
Citizens Upgrades Quince Therapeutics to Market Outperform, Announces $77 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target

PRO
Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82

PRO
Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4

People Also Watch

People Also Watch

Quince Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Quince Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRORodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70

PROCitizens Upgrades Quince Therapeutics to Market Outperform, Announces $77 Price Target

PROCantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target

PROOppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82

PROLeerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4

People Also Watch

People Also Watch

PRO
Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70

PRO
Citizens Upgrades Quince Therapeutics to Market Outperform, Announces $77 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target

PRO
Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82

PRO
Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4